Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

EWS–FLI1 Can Either Create or Inactivate Enhancers in Ewing Sarcoma

DOI: 10.1158/2159-8290.CD-RW2014-230 Published December 2014
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: The EWS–FLI1 fusion protein directly reprograms regulatory circuits in Ewing sarcoma cells.

  • Mechanism: EWS–FLI1 creates enhancers at GGAA repeats and represses conserved enhancers with ETS binding motifs.

  • Impact: Genes activated by EWS–FLI1-driven de novo enhancers may be therapeutic targets in Ewing sarcoma.

Ewing sarcoma is driven by translocations that fuse EWS to FLI1 or other ETS transcription factors. EWS–FLI1 has aberrant transcription factor activity, but how it orchestrates oncogenic gene expression programs is not well understood. Riggi, Knoechel, Gillespie, and colleagues characterized genome-wide EWS–FLI1 binding sites in Ewing sarcoma cell lines and primary tumors and noted enrichment for markers of cis-regulatory enhancer elements. Knockdown of EWS–FLI1 increased histone H3 lysine 27 acetylation, a marker of enhancer activity, at some EWS–FLI1 binding sites, whereas others showed equally strong decreases in this mark. These divergent effects were determined by the DNA sequence of each site: enhancers activated by EWS–FLI1 were significantly enriched for GGAA repeats, whereas most enhancers repressed by EWS–FLI1 contained canonical ETS transcription factor binding motifs. Analysis of evolutionary conservation and the chromatin landscape of other cell types did not indicate that GGAA repeats act as regulatory elements outside of Ewing sarcoma, suggesting that EWS–FLI1 creates de novo enhancers at these loci. Accordingly, expression of EWS–FLI1 in mesenchymal stem cells led to chromatin opening and creation of enhancers. In contrast, enhancers repressed by EWS–FLI1 are highly conserved and active in other mesenchymal cell types. Thus, the displacement of wild-type ETS proteins from these mesenchymal lineage enhancers by EWS–FLI1 may provide a potential explanation for how EWS–FLI1 disrupts mesenchymal differentiation. A strong correlation was observed between EWS–FLI1-bound enhancer activity and proximal gene expression, and several activated genes encode potential drug targets. One such kinase, VRK1, was strongly expressed in all Ewing sarcomas analyzed, and VRK1 knockdown significantly reduced Ewing sarcoma cell proliferation and survival in vitro and in vivo. Together, these results provide mechanistic insights into how EWS–FLI1 reprograms regulatory elements to alter gene expression and point to potential therapeutic targets for Ewing sarcoma.

Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 2014;26:668–81.

Notes

Note: Research Watch is written by Cancer Discovery Science Writers. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

  • ©2014 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 4 (12)
December 2014
Volume 4, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
EWS–FLI1 Can Either Create or Inactivate Enhancers in Ewing Sarcoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
EWS–FLI1 Can Either Create or Inactivate Enhancers in Ewing Sarcoma
Cancer Discov December 1 2014 (4) (12) 1367; DOI: 10.1158/2159-8290.CD-RW2014-230

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
EWS–FLI1 Can Either Create or Inactivate Enhancers in Ewing Sarcoma
Cancer Discov December 1 2014 (4) (12) 1367; DOI: 10.1158/2159-8290.CD-RW2014-230
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Sarcoma

  • SS18-SSX Retargets the BAF Complex to Drive Synovial Sarcoma
  • SS18–SSX Induces the Expression of Neurogenic Genes to Drive Synovial Sarcoma
  • Fusion-Negative Rhabdomyosarcoma Can Arise from Endothelial Cells
Show more Sarcoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement